lapatinib has been researched along with isoxazoles in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (isoxazoles) | Trials (isoxazoles) | Recent Studies (post-2010) (isoxazoles) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 8,633 | 900 | 3,337 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chekaluk, Y; Du, J; Gray, NS; Guo, Y; Kwiatkowski, DJ; Wu, CL; Zhang, J | 1 |
| Choi, J; Hong, YS; Im, HS; Kang, J; Kim, D; Kim, SW; Lee, CH; Lee, DH; Lee, KP; Park, KS; Park, SR; Seo, S; Yoon, S | 1 |
2 other study(ies) available for lapatinib and isoxazoles
| Article | Year |
|---|---|
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Topics: Afatinib; Antibiotics, Antineoplastic; Cell Line, Tumor; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Loss of Heterozygosity; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; Resorcinols; Signal Transduction; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Resorcinols; Signal Transduction; Stomach Neoplasms | 2018 |